Zymeworks Net Income From Continuing Ops from 2010 to 2026
| ZYME Stock | USD 22.72 0.70 3.18% |
Net Loss | First Reported 2015-03-31 | Previous Quarter 2.3 M | Current Value -19.6 M | Quarterly Volatility 56.7 M |
Check Zymeworks Common financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Zymeworks Common's main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.1 M, Interest Expense of 5.8 M or Selling General Administrative of 43.8 M, as well as many indicators such as Price To Sales Ratio of 15.9, Dividend Yield of 0.0 or PTB Ratio of 6.96. Zymeworks financial statements analysis is a perfect complement when working with Zymeworks Common Valuation or Volatility modules.
Zymeworks | Net Income From Continuing Ops | Build AI portfolio with Zymeworks Stock |
Analyzing Zymeworks Common's Net Income From Continuing Ops over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income From Continuing Ops has evolved provides context for assessing Zymeworks Common's current valuation and future prospects.
Latest Zymeworks Common's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Zymeworks Common Stock over the last few years. It is Zymeworks Common's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Zymeworks Common's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Zymeworks Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (61,522,546) | |
| Geometric Mean | 44,742,960 | |
| Coefficient Of Variation | (133.73) | |
| Mean Deviation | 67,637,112 | |
| Median | (33,809,000) | |
| Standard Deviation | 82,276,725 | |
| Sample Variance | 6769.5T | |
| Range | 336.2M | |
| R-Value | (0.47) | |
| Mean Square Error | 5598.4T | |
| R-Squared | 0.22 | |
| Significance | 0.05 | |
| Slope | (7,723,051) | |
| Total Sum of Squares | 108311.4T |
Zymeworks Net Income From Continuing Ops History
About Zymeworks Common Financial Statements
Zymeworks Common stakeholders use historical fundamental indicators, such as Zymeworks Common's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Zymeworks Common investors may analyze each financial statement separately, they are all interrelated. For example, changes in Zymeworks Common's assets and liabilities are reflected in the revenues and expenses on Zymeworks Common's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Zymeworks Common Stock. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -110.4 M | -115.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zymeworks Common Stock is a strong investment it is important to analyze Zymeworks Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zymeworks Common's future performance. For an informed investment choice regarding Zymeworks Stock, refer to the following important reports:Check out the analysis of Zymeworks Common Correlation against competitors. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Will Biotechnology sector continue expanding? Could Zymeworks diversify its offerings? Factors like these will boost the valuation of Zymeworks Common. Anticipated expansion of Zymeworks directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Zymeworks Common data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.85) | Revenue Per Share | Quarterly Revenue Growth 0.726 | Return On Assets | Return On Equity |
Zymeworks Common Stock's market price often diverges from its book value, the accounting figure shown on Zymeworks's balance sheet. Smart investors calculate Zymeworks Common's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Zymeworks Common's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Zymeworks Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zymeworks Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zymeworks Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.